OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium Dec 05, 2019 8:30am EST
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing Dec 04, 2019 9:00am EST
OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements Dec 02, 2019 8:00am EST
OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO™ KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting Nov 12, 2019 8:30am EST
OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting Nov 05, 2019 8:30am EST
OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market Oct 21, 2019 9:00am EDT
OncoSec Announces New Peer-Reviewed Data for TAVO™ in Virus-Associated Skin Cancer Published in Clinical Cancer Research Oct 15, 2019 8:30am EDT
OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries Oct 10, 2019 8:30am EDT
